Advertisement

Updated January 3rd, 2021 at 12:19 IST

India's COVID vaccines: With Covishield & Covaxin nods, Cadilla's phase 3 also approved

The SEC of the CDSCO had made recommendations to the DCGI to grant permission for restricted emergency use of the SII & Bharat Biotech's Covid vaccine

Reported by: Swagata Banerjee
India Covid Vaccine
| Image:self
Advertisement

Drugs Controller General of India (DCGI) has granted permission to vaccines of Serum Institue of India and Bharat Biotech for restricted use in emergency situations on Sunday, essentially approving them for use. The DCGI also announced that Cadila Healthcare Ltd's COVID-19 vaccine using DNA platform technology has been given an approval for phase 3 clinical trials. 

READ | India Approves SII's Covishield & Bharat Biotech's Covaxin COVID Vaccines: DCGI Statement

Cadila Healthcare's COVID-19 vaccine

"The Cadila Healthcare Ltd has has developed a Novel Corona Virus-2019-nCov-Vaccine using DNA platform technology. The firm initiated Phase-I/II clinical trial in India in more than 1000 participants which is ongoing. The interim data suggests that the vaccine is safe and immunogenic with three doses when administered intradermally. Accordingly, firm has sought permission to conduct Phase-III clinical trial in 26000 Indian participants, which has been recommended by the Subject Expert Committee" the DCGI said at the same media briefing where they also announced the approval for Covishield and Covaxin vaccines. 

 READ | Coronavirus LIVE Updates: Covishield, Covaxin Get DCGI Nod; PM Modi Hails Decision

The Subject Expert Committee (SEC) of the Central Drugs Standards Control Organisation (CDSCO) made recommendations to the Drugs Controller General of India to grant permission for restricted emergency use of the Serum Institute of India (SII) and Bharat Biotech's vaccines. As per an official release, the SEC met on Friday and Saturday and made its recommendations in respect of the accelerated approval process request of the SII, Bharat Biotech International Ltd as well as about phase-III trials of Cadila Healthcare Ltd. They also announced that M/s Serum and M/s Bharat Biotech vaccines have to be administered in two doses and all the vaccines have to be stored at 2-8° C. 

READ | Bharat Biotech Recruits 23,000 Volunteers For 3rd Phase Trial Of Covaxin

READ | Bharat Biotech And Ocugen To Co-Develop COVAXIN For U.S. Market

Advertisement

Published January 3rd, 2021 at 12:19 IST

Your Voice. Now Direct.

Send us your views, we’ll publish them. This section is moderated.

Advertisement
Advertisement

Trending Quicks

Ricky Ponting
a few seconds ago
Congress Press Conference
3 minutes ago
Nvidia China chip launch
10 minutes ago
Crew
13 minutes ago
Hardik Pandya and Lasith Malinga
18 minutes ago
Christopher, Wife Emma To Get British Knighthood And Damehood
25 minutes ago
Kendriya Vidyalaya Students
25 minutes ago
The tax notice sent to the Congress party pertains to the assessment years 2017 to 2021.
33 minutes ago
Tie-dye printed shirts
37 minutes ago
A case has been registered against former minister and BRS working president KTR in Hanmakonda
37 minutes ago
Advertisement
Advertisement
Advertisement
Whatsapp logo